291 related articles for article (PubMed ID: 35698032)
1. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine.
Liu J; Wang G; Dan Y; Liu X
J Headache Pain; 2022 Jun; 23(1):68. PubMed ID: 35698032
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods.
Hanci F; Kilinc YB; Kilinc E; Turay S; Dilek M; Kabakus N
Cephalalgia; 2021 Feb; 41(2):166-175. PubMed ID: 32903061
[TBL] [Abstract][Full Text] [Related]
3. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1α are elevated in pediatric migraine attacks.
Kilinc YB; Kilinc E; Danis A; Hanci F; Turay S; Ozge A; Bolay H
Headache; 2023 Sep; 63(8):1076-1086. PubMed ID: 37596867
[TBL] [Abstract][Full Text] [Related]
5. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients.
Tuka B; Helyes Z; Markovics A; Bagoly T; Szolcsányi J; Szabó N; Tóth E; Kincses ZT; Vécsei L; Tajti J
Cephalalgia; 2013 Oct; 33(13):1085-95. PubMed ID: 23598374
[TBL] [Abstract][Full Text] [Related]
6. From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.
Tanaka M; Szabó Á; Körtési T; Szok D; Tajti J; Vécsei L
Cells; 2023 Nov; 12(22):. PubMed ID: 37998384
[TBL] [Abstract][Full Text] [Related]
7. Shared and independent roles of CGRP and PACAP in migraine pathophysiology.
Kuburas A; Russo AF
J Headache Pain; 2023 Apr; 24(1):34. PubMed ID: 37009867
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine.
Zhang Q; Han X; Wu H; Zhang M; Hu G; Dong Z; Yu S
Mol Pain; 2019; 15():1744806918820452. PubMed ID: 30799680
[TBL] [Abstract][Full Text] [Related]
9. Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache.
Guo Z; Czerpaniak K; Zhang J; Cao YQ
Pain; 2021 May; 162(5):1483-1499. PubMed ID: 33252452
[TBL] [Abstract][Full Text] [Related]
10. PACAP Induces Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP.
Kuburas A; Mason BN; Hing B; Wattiez AS; Reis AS; Sowers LP; Moldovan Loomis C; Garcia-Martinez LF; Russo AF
J Neurosci; 2021 May; 41(21):4697-4715. PubMed ID: 33846231
[TBL] [Abstract][Full Text] [Related]
11. High plasma calcitonin gene-related peptide and serum pituitary adenylate cyclase-activating polypeptide levels in patients with neuropathic pain.
Yevgi R; Laloğlu E; Bilge N
Rev Neurol (Paris); 2023 Apr; 179(4):289-296. PubMed ID: 36754669
[TBL] [Abstract][Full Text] [Related]
12. Role of PACAP in migraine: An alternative to CGRP?
Guo S; Jansen-Olesen I; Olesen J; Christensen SL
Neurobiol Dis; 2023 Jan; 176():105946. PubMed ID: 36481434
[TBL] [Abstract][Full Text] [Related]
13. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin/PAC
Rees TA; Labastida-Ramírez A; Rubio-Beltrán E
Trends Pharmacol Sci; 2023 Oct; 44(10):651-663. PubMed ID: 37543479
[TBL] [Abstract][Full Text] [Related]
15. Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system.
Edvinsson JCA; Grell AS; Warfvinge K; Sheykhzade M; Edvinsson L; Haanes KA
Cephalalgia; 2020 Oct; 40(12):1296-1309. PubMed ID: 32486909
[TBL] [Abstract][Full Text] [Related]
16. Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache.
Han X; Dong Z; Hou L; Wan D; Chen M; Tang W; Yu S
Clin Chim Acta; 2015 Oct; 450():151-4. PubMed ID: 26296898
[TBL] [Abstract][Full Text] [Related]
17. Future targets for migraine treatment beyond CGRP.
Al-Hassany L; Boucherie DM; Creeney H; van Drie RWA; Farham F; Favaretto S; Gollion C; Grangeon L; Lyons H; Marschollek K; Onan D; Pensato U; Stanyer E; Waliszewska-Prosół M; Wiels W; Chen HZ; Amin FM;
J Headache Pain; 2023 Jun; 24(1):76. PubMed ID: 37370051
[TBL] [Abstract][Full Text] [Related]
18. The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?
Ernstsen C; Christensen SL; Rasmussen RH; Nielsen BS; Jansen-Olesen I; Olesen J; Kristensen DM
Brain; 2022 Jul; 145(7):2450-2460. PubMed ID: 35136961
[TBL] [Abstract][Full Text] [Related]
19. CGRP and migraine: could PACAP play a role too?
Kaiser EA; Russo AF
Neuropeptides; 2013 Dec; 47(6):451-61. PubMed ID: 24210136
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment.
Dominguez-Moreno R; Do TP; Ashina M
Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):225-231. PubMed ID: 35066541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
